Why Ionis Pharmaceuticals, Inc. (IONS) stock moved
Updated Oct 18, 2026
Ionis Pharmaceuticals, Inc. (IONS) shares fell 2.7% to $42.94 as of October 18, 2026, a moderate decline from the prior close of $44.12. BestStocks flagged the session as a major change for IONS. The move is tied to company news. Below, we break down what changed for IONS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Company News
IONS fell 2.7% in its latest session, moving from $44.12 to $42.94.
NewsLow confidence
Rel. volume
0.5×
Below Avg
Vs peers
—
No comparable peers
Market cap
$7.1B
NASDAQ Global Select
Analyst target
$84
+96.5% vs price
Price chart
Sep 17 – Oct 16
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Ionis Pharmaceuticals, Inc. investors
For Ionis Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Negative session, down 2.7%; Ionis Pharmaceuticals fell 2.20% to $42.71, continuing a persistent technical downtrend that has erased roughly 45% of year-to-date value with no major company-specific negative catalyst released this morning. Wall Street's consensus price target sits at $84.38, implying +96.5% upside from $42.94. Over the past 90 days analysts logged 1 upgrade and 1 downgrade. BestStocks rates the overall signal quality low (43/100). With earnings roughly 17 days out, the next report is the most likely near-term test of the move.
IONS price reaction
IONS last traded at $42.94, down $1.18 (-2.67%) from the previous close of $44.12. The session traded on 0.5× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $42.38 and $46.75, and it currently sits about 13% of the way up that band.
Bullish and bearish analyst opinions on Ionis Pharmaceuticals, Inc. (IONS)
The consensus analyst price target on Ionis Pharmaceuticals, Inc. (IONS) is $84.38, 96.5% above the recent $42.94. Over the past 90 days analysts logged 1 upgrade, 17 maintains, and 1 downgrade. Here is how the bullish and bearish cases on IONS line up.
▲ The bullish case
+Wall Street's consensus price target of $84.38 implies +96.5% upside from $42.94.
+The Street's most bullish target is $115.00 (+167.8%).
+1 analyst upgrade in the past 90 days, most recently UBS to Buy (2026-10-15).
+Positive price momentum.
▼ The bearish case
−1 analyst downgrade in the past 90 days, most recently BMO Capital to Market Perform (2026-08-19).
−Negative session, down 2.7%.
−Ionis Pharmaceuticals fell 2.20% to $42.71, continuing a persistent technical downtrend that has erased roughly 45% of year-to-date value with no major company-specific negative catalyst released this morning.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 18, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Ionis Pharmaceuticals fell 2.20% to $42.71, continuing a persistent technical downtrend that has erased roughly 45% of year-to-date value with no major company-specific negative catalyst released this morning. The stock remains under pressure near its 52-week low of $42.63, weighed by lingering effects from earlier 2026 trial setbacks including the failed Phase 3 CARDIO-TTRansform trial of eplontersen in July and Novartis' failed Phase 3 Lp(a)HORIZON trial for pelacarsen in September. Volume is tracking at 0.28x expected levels 120 minutes into the session.
Ionis Pharmaceuticals, Inc. moved -5.49% intraday from $45.75 to $43.24. ### 📉 Ionis Pharmaceuticals (NASDAQ: IONS ) Slump Ionis Pharmaceuticals shares remain under pressure due to lingering fallout from partner Novartis’ late-stage clinical trial setbacks. ### ⚠️ Key Pressures Weighing on the Stock - Trial Failures: Partner Novartis announced a Phase 3 miss for pelacarsen, followed by a late-stage setback for del-desiran in myotonic dystrophy type 1. - Lost Revenue: The pelacarsen miss eliminates anticipated royalty and milestone economics for Ionis. - Pipeline Scrutiny: The back-to-back failures deepen investor concerns regarding the broader RNA-targeted cardiovascular and neuromuscular pipeline. - Analyst Downgrades: Major Wall Street firms (including Goldman Sachs and Barclays) slashed their price targets following the trial misses. - Overshadowed Approval: Recent FDA approval and commercial pricing for Zanvastro (for Alexander disease) has failed to offset broader pipeline sentiment. Would you like me to review the upcoming catalysts and trial readouts left on Ionis' calendar, or analyze its current cash runway and balance sheet following these setbacks?
Filings2026-09-23-4.0%
Ionis Pharmaceuticals, Inc. (IONS) filed an 8-K on September 23, 2026. The specific content of the filing was not disclosed in available sources.
Ionis Pharmaceuticals shares fell 4.10% to $44.84, pressured by a confluence of sector headwinds and company-specific concerns. Broad healthcare weakness (XLV down over 1%) driven by rising Treasury yields, oil prices above $90/barrel, and U.S.-Iran geopolitical tensions weighed on the biotech sector. Overlaid on that backdrop, lingering investor caution about Ionis's July Phase 3 trial failure for eplontersen and scrutiny over a $546 million equity shelf offering tied to an ESOP further dampened sentiment ahead of the Zilganersen PDUFA decision.
Ionis Pharmaceuticals fell 2.04% to $46.28 following a Phase 3 clinical trial miss for pelacarsen (partnered with Novartis), which failed to meet its primary cardiovascular endpoint, according to reports cited by finance.yahoo.com and marketwatch.com. The decline extends a multi-day selloff triggered by this setback and compounded by July's earlier eplontersen trial failure; volume of 3.0M shares runs 1.55x normal for this point in the session.
Ionis Pharmaceuticals fell 6.75% to $47.97, extending losses driven by recent Phase 3 trial disappointment for pelacarsen (partnered with Novartis) that missed its primary endpoint, compounded by analyst price target cuts from firms including Guggenheim (down to $80) and Barclays following pipeline setbacks earlier in the summer. Volume ran 1.65x normal for this point in the session, reflecting elevated trading activity amid the negative catalyst.
Material / Earnings2026-09-14-5.1%
Ionis Pharmaceuticals, Inc. (IONS) moved −6.51% from $55.02 to $51.44 on 2026-09-14, reaching a new 30-day low on modestly elevated volume (1.4x the 5-day average). The decline occurred amid sector-wide pressure following Novartis's Phase 3 clinical trial failures for rival RNA-targeted cardiovascular and rare-disease therapies (del-desiran and pelacarsen), which sparked contagion selling across biotech peers including IONS.
Material / Earnings2026-09-08-2.4%
Ionis Pharmaceuticals (IONS) moved +8.74% from $52.15 to $56.71 on 2026-09-08, reversing earlier losses after the Phase 3 pelacarsen trial with partner Novartis failed to meet its primary endpoint on September 4. Volume was 3.6x the 5-day average.
In-depth IONS event analyses
Permanent, dated analyses of IONS's most significant sessions.
Why did Ionis Pharmaceuticals, Inc. (IONS) stock move?
IONS fell 2.7% to $42.94. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did IONS stock fall?
IONS lost 2.67% ($1.18) versus the prior close of $44.12, last trading at $42.94 on 0.5× average volume.
When is Ionis Pharmaceuticals, Inc.'s next earnings date?
IONS's next earnings report is estimated for 2026-11-04 — about 17 days away.
What is the analyst price target for IONS?
The consensus analyst price target for IONS is $84.38, about 96.5% above the current $42.94. Over the past 90 days, analysts recorded 1 upgrade, 17 maintains, and 1 downgrade.
How BestStocks tracks IONS
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for IONS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 18, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
